This site provides INTERCEPT product information for International audiences Select your region
The most common method used to prevent TA-GVHD is gamma irradiation. Blood components are exposed to a typical gamma irradiation dose of 2,500 cGy, equalling an inactivation of 5-6 logs of T-cells1, and then selectively transfused into patients most at risk for TA-GVHD. Though proven effective, gamma irradiation has demonstrated a limited safety margin with a rapid decrease in T-cell inactivation correlating with a modest decrease in gamma irradiation dose. In fact, TA-GVHD has been reported in transfusion recipients who received blood components irradiated with 1,500 cGy.2 Another method for reducing lymphocytes in donated blood is leukoreduction; however, this has not been established as a reliable method to prevent TA-GVHD.3
The INTERCEPT™ Blood System offers a comprehensive approach to inactivating pathogens as well as leukocytes. INTERCEPT has been demonstrated as equivalent to gamma irradiation for the prevention of TA-GVHD (CE Mark claim).